Angiopoietin: a TIE(d) balance in tumor angiogenesis
Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular extravasation. These multifaceted pathways present a valuable opportunity in developing novel inhibition strategies for cancer...
Uložené v:
| Vydané v: | Molecular cancer research Ročník 5; číslo 7; s. 655 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.07.2007
|
| Predmet: | |
| ISSN: | 1541-7786 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular extravasation. These multifaceted pathways present a valuable opportunity in developing novel inhibition strategies for cancer treatment. However, the regulatory role of ANG-1 and ANG-2 in tumor angiogenesis remains controversial. There is a complex interplay between complementary yet conflicting roles of both the ANGs in shaping the outcome of angiogenesis. Embryonic vascular development suggests that ANG-1 is crucial in engaging interaction between endothelial and perivascular cells. However, recruitment of perivascular cells by ANG-1 has recently been implicated in its antiangiogenic effect on tumor growth. It is becoming clear that TIE-2 signaling may function in a paracrine and autocrine manner directly on tumor cells because the receptor has been increasingly found in tumor cells. In addition, alpha(5)beta(1) and alpha(v)beta(5) integrins were recently recognized as functional receptors for ANG-1 and ANG-2. Therefore, both the ligands may have wide-ranging functions in cellular activities that affect overall tumor development. Collectively, these TIE-2-dependent and TIE-2-independent activities may account for the conflicting findings of ANG-1 and ANG-2 in tumor angiogenesis. These uncertainties have impeded development of a clear strategy to target this important angiogenic pathway. A better understanding of the molecular basis of ANG-1 and ANG-2 activity in the pathophysiologic regulation of angiogenesis may set the stage for novel therapy targeting this pathway. |
|---|---|
| AbstractList | Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular extravasation. These multifaceted pathways present a valuable opportunity in developing novel inhibition strategies for cancer treatment. However, the regulatory role of ANG-1 and ANG-2 in tumor angiogenesis remains controversial. There is a complex interplay between complementary yet conflicting roles of both the ANGs in shaping the outcome of angiogenesis. Embryonic vascular development suggests that ANG-1 is crucial in engaging interaction between endothelial and perivascular cells. However, recruitment of perivascular cells by ANG-1 has recently been implicated in its antiangiogenic effect on tumor growth. It is becoming clear that TIE-2 signaling may function in a paracrine and autocrine manner directly on tumor cells because the receptor has been increasingly found in tumor cells. In addition, alpha(5)beta(1) and alpha(v)beta(5) integrins were recently recognized as functional receptors for ANG-1 and ANG-2. Therefore, both the ligands may have wide-ranging functions in cellular activities that affect overall tumor development. Collectively, these TIE-2-dependent and TIE-2-independent activities may account for the conflicting findings of ANG-1 and ANG-2 in tumor angiogenesis. These uncertainties have impeded development of a clear strategy to target this important angiogenic pathway. A better understanding of the molecular basis of ANG-1 and ANG-2 activity in the pathophysiologic regulation of angiogenesis may set the stage for novel therapy targeting this pathway.Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular extravasation. These multifaceted pathways present a valuable opportunity in developing novel inhibition strategies for cancer treatment. However, the regulatory role of ANG-1 and ANG-2 in tumor angiogenesis remains controversial. There is a complex interplay between complementary yet conflicting roles of both the ANGs in shaping the outcome of angiogenesis. Embryonic vascular development suggests that ANG-1 is crucial in engaging interaction between endothelial and perivascular cells. However, recruitment of perivascular cells by ANG-1 has recently been implicated in its antiangiogenic effect on tumor growth. It is becoming clear that TIE-2 signaling may function in a paracrine and autocrine manner directly on tumor cells because the receptor has been increasingly found in tumor cells. In addition, alpha(5)beta(1) and alpha(v)beta(5) integrins were recently recognized as functional receptors for ANG-1 and ANG-2. Therefore, both the ligands may have wide-ranging functions in cellular activities that affect overall tumor development. Collectively, these TIE-2-dependent and TIE-2-independent activities may account for the conflicting findings of ANG-1 and ANG-2 in tumor angiogenesis. These uncertainties have impeded development of a clear strategy to target this important angiogenic pathway. A better understanding of the molecular basis of ANG-1 and ANG-2 activity in the pathophysiologic regulation of angiogenesis may set the stage for novel therapy targeting this pathway. Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular extravasation. These multifaceted pathways present a valuable opportunity in developing novel inhibition strategies for cancer treatment. However, the regulatory role of ANG-1 and ANG-2 in tumor angiogenesis remains controversial. There is a complex interplay between complementary yet conflicting roles of both the ANGs in shaping the outcome of angiogenesis. Embryonic vascular development suggests that ANG-1 is crucial in engaging interaction between endothelial and perivascular cells. However, recruitment of perivascular cells by ANG-1 has recently been implicated in its antiangiogenic effect on tumor growth. It is becoming clear that TIE-2 signaling may function in a paracrine and autocrine manner directly on tumor cells because the receptor has been increasingly found in tumor cells. In addition, alpha(5)beta(1) and alpha(v)beta(5) integrins were recently recognized as functional receptors for ANG-1 and ANG-2. Therefore, both the ligands may have wide-ranging functions in cellular activities that affect overall tumor development. Collectively, these TIE-2-dependent and TIE-2-independent activities may account for the conflicting findings of ANG-1 and ANG-2 in tumor angiogenesis. These uncertainties have impeded development of a clear strategy to target this important angiogenic pathway. A better understanding of the molecular basis of ANG-1 and ANG-2 activity in the pathophysiologic regulation of angiogenesis may set the stage for novel therapy targeting this pathway. |
| Author | Wong, Philip E H Shim, Winston S N Ho, Ivy A W |
| Author_xml | – sequence: 1 givenname: Winston S N surname: Shim fullname: Shim, Winston S N email: surssnw@nus.edu.sg organization: Research and Development Unit, National Heart Centre, 17 Third Hospital Avenue, Singapore 168752, Singapore. surssnw@nus.edu.sg – sequence: 2 givenname: Ivy A W surname: Ho fullname: Ho, Ivy A W – sequence: 3 givenname: Philip E H surname: Wong fullname: Wong, Philip E H |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17634421$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9j01Lw0AYhPdQsR_6E5ScRA-p77vZr3orpWqh4KWew2bzbllpNjWbHPz3VqxeZmB4GGambBTbSIzdIMwRpXlEKTDX2qh547ocdA6g-YhN_vMxm6b0AcABtbpk45MWQnCcMLGM-9Ae20B9iE-ZzXab9X39kFX2YKOjLMSsH5q2y-wPt6dIKaQrduHtIdH12Wfs_Xm9W73m27eXzWq5zZ0wvM-xcgZtbauFIHDee1k4JaqaFkWlvCSjCleAAm1AopXeIyAuamfAeqGs4zN299t77NrPgVJfNiE5OpymUTukUoNWXBTyBN6ewaFqqC6PXWhs91X-_eTf3i1U6g |
| CitedBy_id | crossref_primary_10_1186_1471_2407_14_167 crossref_primary_10_1016_j_neuroscience_2011_05_058 crossref_primary_10_1080_2162402X_2019_1629779 crossref_primary_10_1002_hep_28024 crossref_primary_10_1177_1534734615600590 crossref_primary_10_1158_1078_0432_CCR_09_1924 crossref_primary_10_2527_jas_2011_4594 crossref_primary_10_1016_j_yexcr_2011_06_008 crossref_primary_10_1371_journal_pone_0034758 crossref_primary_10_1016_j_jpedsurg_2009_06_023 crossref_primary_10_1038_s41392_023_01460_1 crossref_primary_10_1016_j_canlet_2013_04_028 crossref_primary_10_1053_j_seminoncol_2014_02_007 crossref_primary_10_1007_s00432_012_1282_3 crossref_primary_10_1016_j_beem_2010_10_004 crossref_primary_10_1111_exd_12698 crossref_primary_10_1038_mt_2008_112 crossref_primary_10_1002_jor_23507 crossref_primary_10_1111_jop_12574 crossref_primary_10_1016_j_canlet_2012_08_018 crossref_primary_10_1242_dev_115386 crossref_primary_10_1517_13543784_2011_549125 crossref_primary_10_3892_ol_2017_6203 crossref_primary_10_1038_s41388_020_01411_y crossref_primary_10_1517_13543784_2013_793306 crossref_primary_10_1016_j_bbcan_2014_05_002 crossref_primary_10_1016_j_jim_2013_07_010 crossref_primary_10_1159_000529774 crossref_primary_10_3389_fonc_2015_00165 crossref_primary_10_1038_sj_bjc_6605219 crossref_primary_10_1517_14728214_2010_486788 crossref_primary_10_1016_j_jmig_2016_01_025 crossref_primary_10_3389_fonc_2020_612802 crossref_primary_10_1096_fj_11_182287 crossref_primary_10_2353_ajpath_2009_090391 crossref_primary_10_1002_jso_24249 crossref_primary_10_1016_j_critrevonc_2015_02_001 crossref_primary_10_1158_1078_0432_CCR_17_1775 crossref_primary_10_1002_jez_b_22449 crossref_primary_10_1002_hep_23700 crossref_primary_10_1016_j_lfs_2021_119406 crossref_primary_10_1161_CIRCGENETICS_114_000597 crossref_primary_10_1007_s00280_015_2689_8 crossref_primary_10_1111_j_1743_6109_2009_01648_x crossref_primary_10_1007_s00403_012_1228_2 crossref_primary_10_1097_PPO_0b013e31829d5d15 crossref_primary_10_1016_j_exer_2019_04_015 crossref_primary_10_1530_REP_17_0597 crossref_primary_10_3390_ijms17091489 crossref_primary_10_3390_ijms23136934 crossref_primary_10_1002_path_4304 crossref_primary_10_1007_s00277_013_1759_4 crossref_primary_10_1593_neo_81480 crossref_primary_10_1007_s00018_019_03351_7 crossref_primary_10_1007_s12105_011_0302_y crossref_primary_10_1007_s10620_010_1327_x crossref_primary_10_1111_j_1349_7006_2010_01692_x crossref_primary_10_3390_life12122092 crossref_primary_10_1083_jcb_200811159 crossref_primary_10_3892_ijo_2013_2076 crossref_primary_10_1016_j_genrep_2022_101638 crossref_primary_10_3389_fonc_2025_1529225 crossref_primary_10_1016_j_semcancer_2009_05_002 crossref_primary_10_1038_sj_bjc_6604426 crossref_primary_10_1371_journal_pone_0066143 crossref_primary_10_3390_medicina57111191 crossref_primary_10_3390_ijms21165840 crossref_primary_10_1007_s00580_010_1000_y crossref_primary_10_1177_1010428317711658 crossref_primary_10_1016_j_jacc_2013_09_019 crossref_primary_10_1158_0008_5472_CAN_09_4125 crossref_primary_10_1016_j_jim_2010_02_008 crossref_primary_10_1134_S0026893312060076 crossref_primary_10_1002_glia_22411 crossref_primary_10_1517_14656566_2016_1161027 crossref_primary_10_1007_s12013_008_9040_5 crossref_primary_10_1158_0008_5472_CAN_09_3549 crossref_primary_10_1016_j_fertnstert_2011_05_041 crossref_primary_10_1053_j_seminoncol_2009_02_002 crossref_primary_10_1016_j_ccr_2010_07_001 crossref_primary_10_1517_13543780903485659 crossref_primary_10_1182_blood_2007_12_130021 crossref_primary_10_1007_s00580_011_1256_x crossref_primary_10_1073_pnas_0914619107 crossref_primary_10_1007_s12288_015_0548_8 crossref_primary_10_3390_pathophysiology31040043 crossref_primary_10_1016_j_lungcan_2009_03_002 crossref_primary_10_1155_2008_945275 crossref_primary_10_1038_onc_2008_304 crossref_primary_10_1186_s12935_024_03544_6 crossref_primary_10_1038_nrurol_2009_262 crossref_primary_10_1016_j_jbspin_2010_06_004 crossref_primary_10_1016_j_stem_2009_06_001 crossref_primary_10_1016_j_yexcr_2014_10_017 crossref_primary_10_1007_s11912_009_0017_3 crossref_primary_10_1016_S1169_8330_10_70002_8 crossref_primary_10_3892_etm_2015_2280 crossref_primary_10_1080_07357900701662509 crossref_primary_10_1007_s12032_013_0571_2 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1541-7786.mcr-07-0072 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| ExternalDocumentID | 17634421 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .55 .GJ 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABEFU ACGFO ACPRK ADBBV ADCOW AENEX AFFNX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 HH5 H~9 IH2 KQ8 L7B MVM NPM OK1 QTD RCR RHI TR2 W8F WHG WOQ X7M YKV ZGI 7X8 |
| ID | FETCH-LOGICAL-c482t-1bc81adab94e0cfff53c64bde93b6f5e863c306078051a5ff10119dc80af46ac2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 136 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000248200700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1541-7786 |
| IngestDate | Fri Sep 05 14:57:20 EDT 2025 Mon Jul 21 06:04:09 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c482t-1bc81adab94e0cfff53c64bde93b6f5e863c306078051a5ff10119dc80af46ac2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://scholarbank.nus.edu.sg/handle/10635/24088 |
| PMID | 17634421 |
| PQID | 70762435 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_70762435 pubmed_primary_17634421 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-Jul 20070701 |
| PublicationDateYYYYMMDD | 2007-07-01 |
| PublicationDate_xml | – month: 07 year: 2007 text: 2007-Jul |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2007 |
| SSID | ssj0020176 |
| Score | 2.2947066 |
| SecondaryResourceType | review_article |
| Snippet | Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have wide-ranging effects on tumor malignancy that includes angiogenesis,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 655 |
| SubjectTerms | Angiopoietins - chemistry Angiopoietins - metabolism Animals Humans Neoplasms - blood supply Neovascularization, Pathologic - pathology Receptors, TIE - chemistry Receptors, TIE - metabolism |
| Title | Angiopoietin: a TIE(d) balance in tumor angiogenesis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17634421 https://www.proquest.com/docview/70762435 |
| Volume | 5 |
| WOSCitedRecordID | wos000248200700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFH5Uq-LFpW51zcGDHmInM5lNBCmlRcGWIlV6GzJZyhycqV0E_73JLL2JBy85hAwML8lb8t73PoBrwYWrQ2mOY-E7mDLh49DzKWYG98kNWDNniXh_8QeDYDwOhzV4qLAwpqyy0om5ohYZN2_kLV8H3La27Y_TT2w4o0xutSTQWIO6ox0ZU9Dlj1c5BG3Zcmo57SMQbLqklfgd4gat1dxdv_OaF19aeYvgX3zM3Nb0dv_3l3uwU_qYqF0cin2oybQBmwXr5HcDtvplPv0AaDudJNk0Swzw-R4xNHru3ohbFJuCRy5RkqLF8iObIWbWTYxeTOaH8NbrjjpPuORRwJwG9gKTmAeECRaHVFpcKeU63KOxkKETe8qVgedwHTlYht6AMFcpYhrBCR5YTFGPcfsI1tMslSeAeKhsN7aodM3t10sUsZmyqKMok8qTTbiq5BLpc2qSDyyV2XIeVZJpwnEh2mhatNOI9DY5lNrk9M9vz2C7elq1yDnUlb6h8gI2-Ncimc8u8-3X42DY_wHmErch |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Angiopoietin%3A+a+TIE%28d%29+balance+in+tumor+angiogenesis&rft.jtitle=Molecular+cancer+research&rft.au=Shim%2C+Winston+S+N&rft.au=Ho%2C+Ivy+A+W&rft.au=Wong%2C+Philip+E+H&rft.date=2007-07-01&rft.issn=1541-7786&rft.volume=5&rft.issue=7&rft.spage=655&rft_id=info:doi/10.1158%2F1541-7786.MCR-07-0072&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-7786&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-7786&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-7786&client=summon |